ArticleAnnals of medicine2026
Association between anti-nephrin autoantibodies and disease activity in minimal change disease.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimal change disease (MCD) is a podocytopathy linked to immune-mediated mechanisms, with emerging evidence suggesting the presence of anti-nephrin autoantibodies in a subset of patients. Given that Th2-type immune responses can promote IgG subclass switching to IgG4, this study aimed to characterize the distribution of these autoantibodies across disease stages, their correlation with clinical parameters, and to investigate their IgG subclass distribution and potential Th2 immune skewing.
methodsThis bi-centric study included 60 patients with MCD (including pediatric cases), 125 with other glomerular diseases, and 40 healthy controls. An affinity capture-elution ELISA was used to quantify serum anti-nephrin autoantibodies, evaluate their correlation with disease activity, and characterize their IgG subclass distribution. In addition, serum Th1/Th2 cytokine profiles were measured using Olink proteomics technology to assess Th2 immune skewing.
resultsAmong 60 biopsy-confirmed MCD patients, circulating anti-nephrin autoantibodies were detected in 50% of cases. Notably, 70% of patients in the active phase tested positive for anti-nephrin autoantibodies, exhibiting significantly elevated antibody levels compared to those in partial or complete remission. Anti-nephrin levels positively correlated with proteinuria, and inversely with serum albumin and estimated glomerular filtration rate. Furthermore, patients positive for anti-nephrin autoantibodies had higher proteinuria, more severe dyslipidemia, and worse renal function compared to autoantibody-negative patients. Moreover, anti-nephrin antibody-positive MCD patients displayed a predominant IgG4 subclass alongside elevated serum IL-4 and IL-13 levels and an increased IL-4/IFN-γ ratio, supporting a Th2-skewed immune status.
conclusionAnti-nephrin autoantibodies are associated with disease activity in MCD, exhibit an IgG4-predominant subclass, and are accompanied by a Th2-skewed cytokine profile. These findings suggest their potential as a noninvasive biomarker, warranting further prospective studies to validate their clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.